Appointment of Finance Director

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Sep 11, 2001

GW is pleased to announce the appointment of David Kirk as Finance Director, with immediate effect. Mr Kirk succeeds Jonathan Laughton who steps down from the Board but will continue in his role of Company Secretary and becomes Financial Controller.

David Kirk (age 47) joined Arthur Andersen in 1975, qualifying as a Chartered Accountant in 1978 and becoming a partner in 1988. At Arthur Andersen he specialised in entrepreneurial growth companies and worked across a range of sectors. He was responsible for launching the UK Arthur Andersen Biotech Programme in 1994 whilst Head of its UK Technology Team.

In early 1997 he became the first Finance Director of CeNeS Limited, the company developing drugs for CNS disorders and pain control, playing a significant role in its development, including its reverse into Core Group PLC (which subsequently became CeNeS Pharmaceuticals Plc). He left CeNeS in summer 2000. He was also a founding Director of Amura Limited, an antibacterial research company, and was until June 2001 a non executive Director of Avlar Bioventures, a biotechnology venture capital fund based in Cambridge.

Dr Geoffrey Guy, Executive Chairman, commented: "David is well known to GW and has already worked with the Company in a consultancy capacity. I am delighted to welcome him to the Board. His extensive financial and healthcare experience will be of great benefit to the Company as we expand our late stage clinical programme and scale up operations ahead of market launch."

"As Finance Director, Jonathan has played a vital role in the early years of GW's life and we look forward to his continuing contribution to the Company's development."

David Kirk, commented: "Over recent months, I have come to know GW well and am very excited by the Company's prospects. I look forward to working with the GW board and management team at this very important time in the Company's development."

A list of David Kirk's current and former directorships is attached as an appendix to this announcement.
Enquiries:  

GW Pharmaceuticals plc  (11/09/01) 020 7601 1000
Dr Geoffrey Guy, Executive Chairman  (Thereafter) 01980 619 000
Justin Gover, Managing Director  
David Kirk, Finance Director  

Square Mile BSMG Worldwide  020 7601 1000
Kevin Smith/Graham Herring  

Website  
www.gwpharm.com

Appendix

DAVID FRANCIS KIRK - LIST OF CURRENT AND FORMER DIRECTORSHIPS & PARTNERSHIPS

Former directorships or partnerships held since 1 September 1996:

CENES PHARMACEUTICALS PLC
CENES DRUG DELIVERY LIMITED
CENES RESEARCH LIMITED
CENES LIMITED
CENES CONTRACT RESEARCH LIMITED
EQUADOR PLC
EQUADOR CONSULTING LIMITED
EQUADOR GROUP SERVICES LIMITED
AMURA LIMITED
AVLAR BIOVENTURES LIMITED
QUANTUM HEALTHCARE FUND (CARRIED INTEREST PARTNER) LTD
QUANTUM HEALTHCARE FUND (GENERAL PARTNER) LIMITED
ACLAR LIMITED
PINCO 830 LIMITED - DISSOLVED JUNE 1998
THE LEO BAECK COLLEGE
DKASSOCIATES

Current directorships:
PINCO 1182 LIMITED

There are no further disclosures to be made in respect of David Kirk pursuant to paragraph (f) of Schedule 2 of the AiM Rules for companies.

Recent News